1. Augmedix, Inc. (NADAQ:AUGX)
Number of Hedge Fund Investors: 27
Augmedix, Inc. (NADAQ:AUGX), a San Francisco-based healthcare technology company, offers live clinical support services and remote medical documentation solutions to the top healthcare systems in the United States using ambient AI technology. Augmedix Live and Augmedix Notes are its systems, which include pre-visit documentation (pre-charting and digitizing of prior records/patient history), during-visit documentation, post-visit documentation, and an after-visit summary. Using mobile devices, clinicians may access its apps.
Following the company’s reduction of its full-year expectation and guidance for lower-than-expected revenue for the period, Augmedix’s shares saw a 41% drop in May 2024. In FY 2023, the company’s net loss in terms of revenue was -$19.2 million, while its adjusted EBITDA loss was -$15.2 million, indicating continued unprofitability. Cash flow concerns continue, with a $15 million operational cash flow burn and a reliance on $43 million obtained through financing operations to boost its cash balance. This has allowed AUGX to more than double its cash position YoY to $46 million in fiscal year 2023 while burning down $15 million in cash from operations. With a current trade price of $0.89, the stock is down more than 84% year to date and has returned more than 82% since its IPO. Concerns exist over profitability and the requirement for additional capital raising. It’s operating income has been negative over the years.
As per Grand View Research, the AI-driven healthcare sector, which is expected to grow at a 29.3% CAGR and reach $22 billion by 2030, presents an opportunity for Augmedix (NASDAQ: AUGX). In 2023, the company’s annual revenue growth rate exceeded 45%, outperforming the market. The company, being a leader in ambient AI medical documentation and data solutions, has shown strong financial performance, with annual revenue increasing every year. Revenue surged from $22.17 million in 2021 to $30.93 million in 2022 and then $44.85 million in 2023, further increasing to $48.70 million during the last 12 months. Strong client demand and the effective implementation of their new AI-powered medical documentation solutions have resulted in a rise in Augmedix’s revenue.
Its robust clientele includes HCA Healthcare and Dignity Health. Augmedix reported total sales of $13.5 million in Q1 2024, a 40% increase from the same quarter last year, despite an adjusted EBITDA loss of $5.1 million, outperforming projections and consensus. The reported quarterly EPS of $0.12 was in line with analysts’ expectations.
Augmedix Go’s testing in an emergency department environment with HCA Healthcare, as well as its anticipated full launch in March 2024, demonstrate the potential for product growth and higher market penetration. Furthermore, Augmedix’s business plan calls for recurrent monthly payments under annual agreements, indicating a steady and predictable source of income.
While we acknowledge the potential of penny stocks, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AUGX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: Analyst Sees a New $25 Billion “Opportunity” for NVIDIA and Jim Cramer is Recommending These 10 Stocks in June.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also look at the 10 Best Residential Real Estate Stocks to Buy and the 7 Best AI Value Stocks That are ‘Money Machines’ According to NYU’s Aswath Damodaran.
